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ABSTRACT 
The human genome has two copies of the Survival Motor Neuron (SMN) gene, SMN1 and 
SMN2. The absence of SMN1 results in spinal muscular atrophy (SMA), a leading genetic 
disease among infants and children. SMN2 cannot substitute for SMN1 because of exon 7 
skipping. While restoring exon 7 inclusion in SMN2 is a promising approach for SMA therapy, 
the method has limitations for specific SMA patients carrying a single SMN2 allele. Recently, a 
severe SMA patient carrying a single SMN2 allele as well as a SMN1 allele with a deleterious G-
to-C mutation (G1C) at the splice donor site of intron 7 has been reported. In this study, we show 
that an engineered U1 small nuclear ribonucleoprotein (eU1 snRNP) with extended base pairing 
at the 5′ splice site of intron 7 prevents skipping of exon 7 of SMN1 carrying the G1C mutation. 
We also show that eU1 snRNA promotes expression of the full length SMN protein from the 
SMN1 allele carrying the G1C mutation. We further demonstrate that eU1 snRNAs annealing to 
5′ splice site-like sequences downstream of the canonical intron 7 splice donor site can activate 
these sites and promote the inclusion of an extended exon 7 from SMN1 carrying the G1C 
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CHAPTER 1. GENERAL INTRODUCTION 
RNA splicing is a complex process that involves macromolecular machinery and cis-regulatory 
elements. A key component to RNA splicing is the U1 small nuclear ribonucleoprotein (U1 
snRNP), which is composed of a 165 bp snRNA strand containing four stem-loop structures that 
interact with at least protein factors U1-A, U1-70K, U1-C, and Smith (Sm) proteins (Rogalska et 
al., 2016). The Sm proteins, which are common to all snRNP complexes, include SmB, SmD1, 
SmD2, SmD3, SmE, SmF, and SmG (Figure 1; Buratti & Baralle, 2010). During splicing, the 
U1-C component of the U1 snRNP recognizes the 5ʹ′ splice site (5ʹ′ss) of an exon, which typically 
contains a GU residue, before pre-mRNA/U1 snRNA base pairing takes place (Du and Rosbash, 
2002). In vertebrates and S. cerevisiae, U1 snRNAs contain two pseudouridines in a conserved 
AUACΨΨACCU sequence at the 5ʹ′ end (Wu et al., 2011). Downstream of the 5ʹ′ss, protein 
factor SF1/mBBP recognizes a branchpoint adenine and recruits the U2AF protein. The U2 
snRNP is recruited to the branchpoint site and displaces SF1/mBBP and U2AF (Buratti & 
Baralle, 2010). In the process, the U1-70K protein component of the U1 snRNP, which binds to a 
consensus GAUCANGAAG motif in stem-loop I, interacts with exonic splicing enhancers to 
promote exon definition (Surowy et al., 1989; Rogalska et al., 2016). The stem-loop IV structure 
of the U1 snRNP interacts with the SF3A1 protein component of U2 to promote intron definition 
(Rogalska et al., 2016). The resulting cross-exon complex recruits a tri-snRNP containing U4, 
U5, and U6 to form the spliceosome complex that catalyzes intron excision and exon ligation 
(Wahl et al., 2016). Protein factors further regulate splicing by binding to exonic or intronic 
splicing enhancers and silencers that define splice sites and enable alternative splicing that can 
allow a gene to express more than one type of transcript (Wang & Burge, 2008).  
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Diseases that involve the U1 snRNP emphasize the impact the ribonucleoprotein has on 
an organism. Amyotrophic lateral sclerosis (ALS), a fatal adult motor neuron disease, is partly 
caused by U1 snRNP loss of function when mutations in the RNA-binding protein FUS inhibit 
association between FUS and U1 snRNP. FUS carrying mutations such as R495X and P525L 
mislocalize in the cytoplasm and have reduced interactions with U1 snRNP, while FUS carrying 
mutations such as R521G have reduced binding to U1 snRNP (Calvo et al., 2014; Yu et al., 
2015; Sun et al., 2015). Cerebro-costo-mandibular syndrome, a malformation disorder, is caused 
by deleterious mutations in SNRPB, the gene that encodes snRNP components SmB and SmBʹ′. 
Mutations in the second intron of SNRPB such as c.164G>C, c.164G>T, c.165G>C, c.166G>C, 
and c.213+57C>A favor the inclusion of an alternative exon that carries a premature stop codon 
and reduces the translation of functional SmB and SmBʹ′ for assembling snRNPs (Lynch et al., 
2014; Bacrot et al., 2015). Alzheimer’s disease (AD) is another condition that may partly involve 
disrupting U1 snRNP splicing activities. U1 snRNP components U1-70K and U1A are among 
the proteins that aggregate in the brain tissue of AD patients, while splicing deficiency, 
premature cleavage, and polyadenylation on cryptic poly(A) sites increase in frequency (Bai et 
al., 2013). Additionally, HMGA1a, a protein that has increased expression in the brain tissue of 
sporadic AD patients, forms a complex with the U1 snRNP that inhibits dissociation of U1 
snRNP from positions such as the 5ʹ′ splice site of exon 5 in PS2 and impedes RNA splicing (Ohe 
& Mayeda, 2010). In autoimmune disorders such as systemic lupus erythematosus (SLE), the U1 
snRNP itself can trigger inflammation after T and B cells are exposed to the U1-70K component 
from apoptotic cells (Greidinger et al., 2002; Shin et al., 2012). 
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In genetic diseases, 50 to 60% of deleterious mutations disrupt RNA splicing (Wang & 
Cooper, 2007). Familial dysautonomia (FD), an autosomal recessive disorder in which low levels 
of IKAP protein cause progressive degeneration of the sensory and autonomic nervous systems, 
often appears to be the result of a T-to-C mutation at base pair 6 in intron 20 of IKBKAP 
(Slaugenhaupt et al., 2001). The T-to-C mutation apparently weakens the already weak splicing 
signals surrounding exon 20 in IKBKAP and promotes exon skipping (Ibrahim et al., 2007). 
Individuals afflicted with Bardet-Biedl syndrome (BBS), a malformation syndrome, often carry 
mutations at BBS1, a gene necessary for proper assembly of the BBSome, which is involved in 
transporting proteins to cilia. In one family affected by BBS, a G-to-A mutation in the last 
position of exon 5 in BBS1, which is part of the splice donor site, was found to be triggering 
exon 5 skipping (Schmid et al., 2011). Netherton syndrome, a severe autosomal recessive skin 
disorder, can be caused by a variety of mutations at SPINK5. Mutations affecting splice donor 
sites in SPINK5 have included a G-to-A mutation in the last position of exon 1, a T-to-A 
mutation in the second position of intron 2, a G-to-A mutation at the fifth position of intron 2, 
and a G-to-A mutation in the first position of intron 23 (Bitoun et al., 2002). Splice acceptor sites 
in SPINK5 have been disrupted by mutations such as a G-to-A mutation in the last position of 
intron 20 and a G-to-A mutation at the last position of intron 17 (Bitoun et al., 2002). 
Additionally, a C-to-T mutation in the ninth position of exon 11 in SPINK5 was shown 
promoting exon skipping by strengthening hnRNPA1 binding sites, while weakening Tra2β 
binding sites (Dal Mas, Fortugno, et al., 2015). Cystic fibrosis is triggered by deleterious CFTR 
alleles that alter chloride secretion across the apical membrane of epithelial cells. In CFTR, 
splice donor sites may be disrupted by mutations such as a G-to-T mutation at the first position 
of intron 5, a G-to-A mutation at the fifth position of intron 14b, and a G-to-A mutation at the 
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first position of intron 23 (Fanen et al., 1992). Also, a G-to-A mutation at the last position of 
intron 10 in CFTR disrupts a splice acceptor site, while an A-to-G mutation within intron 17a at 
position -26 generates an alternative splice acceptor site (Fanen et al., 1992). In intron 11 of 
CFTR, an A-to-G mutation at position 1.6 kb produces a new exon (Chillon et al., 1995). In cases 
of cancer, mutations affecting splicing have been detected in tumor suppressor genes. Notably, 
cancer patients have carried mutations such as a G-to-A mutation in the first position of intron 7 
in hSNF5, a G-to-T mutation at the last position of intron 3 in APC, and a G-to-A mutation in the 
last position of exon 4 in CCND1 (Venables, 2004; Friedl & Aretz, 2005; David & Manley, 
2010; Eaton et al., 2011).  
 
Mutations that induce aberrant splicing are especially prevalent in cases of spinal 
muscular atrophy (SMA). SMA is both the second most common autosomal recessive disorder 
and a leading hereditary cause of infant death (Lefebvre et al., 1995; Prior, 2007). The disorder is 
caused by deletions or mutations within the SMN1 gene, which typically encodes the Survival 
Motor Neuron protein (SMN) that has multiple, vital functions in cellular metabolism (Singh & 
Singh, 2011). SMA patients suffer from not having enough SMN protein, which causes anterior 
horn cells of the spinal cord to degenerate and results in progressive limb and trunk paralysis 
(Lefebvre et al., 1995). SMN2, an almost identical duplicate of SMN1 that is unique to humans, 
cannot compensate for the loss of SMN1 due to a C-to-T mutation at the 6th position of exon 7 
that promotes exon 7 skipping and consequently produces low levels of full-length SMN protein 
(Lefebvre et al., 1995; Lorson et al., 1999; Rochette et al., 2001). In conjunction with a UUA 
codon that is located between positions 43 and 45 in human exon 7, the C-to-T mutation may 
have evolved to cap SMN levels after the SMN gene duplicated in the human lineage (Singh et 
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al., 2004). Exon 7 inclusion in SMN genes is also mediated by cis-enhancers and silencers such 
as SF2/ASF and ISS-N1, respectively (Figure 2; Singh et al., 2007). 
 
While SMN2 can still produce enough full-length transcript for most types of cells, SMN2 
cannot support motor neurons and muscle cells (Boyer et al., 2013). Since almost all SMA 
patients at least still carry SMN2, research for developing SMA therapy has often involved trying 
to correct SMN2 splicing to include exon 7 (Singh and Singh, 2011; Howell et al., 2014). SMA 
patients who retain a copy of SMN1 carry a variety of mutations that cause a loss of SMN 
function. While null alleles of SMN1 are often caused by missense mutations or deletions, 
relatively rare SMN1 mutations that cause splice-site changes have also been reported. One 
recently identified SMN1 mutation is a G-to-C substitution at the exon 7 splice donor site that 
induces exon 7 skipping during RNA splicing (Ronchi et al., 2015).  
 
 One potential method for correcting splicing in deleterious SMN1 alleles such as the 
mutant carrying the G-to-C substitution at the exon 7 splice donor site is to increase base pairing 
between U1 snRNA and the 5ʹ′ss of exon 7. In SMN1 mutants carrying mutations at exon 7, 
mutated U1 snRNA can promote splicing in the presence of RNA structures that typically inhibit 
U1 snRNP binding at the 5′ss of exon 7 (Figure 3; Singh et al., 2007). Similarly, in BBS1 mini-
genes carrying mutations at the splice donor site of exon 5 that induce exon skipping, U1 
snRNAs designed to base pair with mutated splice donor sites have been shown to restore exon 5 
(Schmid et al., 2013). Alternatively, U1 snRNAs designed to bind to intronic sequences 
downstream of a canonical splice site can also correct splice defects. In a SPINK5 mutant that 
exhibits exon 11 skipping, F9 mutants that exhibit exon 5 skipping, CFTR mutants that exhibit 
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exon 12 skipping, and in SMN2, U1 snRNAs that target sequences downstream of splice donor 
sites can inhibit exon skipping by apparently recruiting splicing factors onto an upstream exon 
(Dal Mas, Fortugno, et al., 2015; Alanis et al., 2012; Dal Mas, Rogalska, et al., 2015).  
 
In Chapter 2, we demonstrate that, in the context of the SMN1 mutant minigene carrying 
a G-to-C substitution at the exon 7 splice donor site, U1 snRNAs modified to bind to the 
mutation site can prevent exon 7 skipping. Modified U1 snRNAs targeting the mutated 5ʹ′ splice 
site of exon 7 both strongly promote intron 7 retention and weakly activate cryptic splice sites 
that allow elongated versions of exon 7 to be included during splicing. Additionally, we show 
that U1 snRNAs designed to bind to potential splice sites downstream of the mutated exon 7 
splice donor site can promote the inclusion of elongated versions of exon 7 greatly enough to 
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FIGURE LEGENDS 
 
Figure 1. Diagrammatic represenation of U1 snRNP annealed to the 5′ splice site (5′ss) of exon 
7 in SMN1. The U1 snRNP contains four stem-loop structures that interact with U1-A, U1-70K, 
U1-C, and the Smith proteins SmB, SmD1, SmD2, SmD3, SmE, SmF, and SmG (Rogalska et al. 
2016; Buratti & Baralle, 2010). The boxes represent exon 7 (E7) and exon 8 (E8) of SMN1, 
while the line connecting the two boxes represents intron 7. Circles and ovals represent U1 
snRNP protein factors. The upper case letters in the SMN1 sequence indicate exonic nucleotides 
while lower case letters indicate intronic nucleotides. Numbering starts from the first position of 
intron 7. 
 
Figure 2. Diagrammatic representation of known splicing regulatory elements in exon 7 and 
intron 7 of SMN1. Binding sites for SF2/ASF and Tra2-β1 are positive (+) cis-elements that 
promote exon 7 inclusion. Negative (-) cis-elements Extinct, the hnRNP A1 binding site, 3′-
Cluster, and ISS-N1 promote exon 7 skipping. TSL2 is an RNA stem-loop structure that 
promotes exon 7 skipping (Singh et al. 2007). Upper case letters indicate exonic sequences while 
lower case letters indicate intronic sequences. Numbering starts from the first position of intron 
7. 
 
Figure 3. Diagrammatic representation of engineered U1 snRNA that promoted exon 7 inclusion 
in SMN1 minigenes that carried mutations strengthening TSL2. The engineered U1 snRNA also 
promoted exon 7 inclusion in SMN2 minigenes (Singh et al. 2007). Mutated nucleotides as 
compared to the wild-type snRNA are shown in red. Black circles indicate Watson-Crick and 
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wobble base pairs formed between U1 snRNAs and the 5′ss of exon 7. Upper case letters 
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Figure 2. Diagrammatic representation of known splicing regulatory elements in exon 7 and 
intron 7 of SMN1.	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CHAPTER 2. AN ENGINEERED U1 SNRNP REDEFINES SMN1 EXON 7 CARRYING 
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ABSTRACT 
Humans carry two highly similar copies of the survival motor neuron (SMN) gene, SMN1 
and SMN2. Most spinal muscular atrophy (SMA) patients lack a functional copy of SMN1. SMN2 
is prone to exon 7 skipping and cannot compensate for the loss of SMN1. Previous research in 
developing treatments for SMA has focused on preventing exon 7 skipping in SMN2, but the 
approach has limitations for patients carrying a single SMN2 and pathogenic mutations that 
disable splice sites of SMN1 exon 7. Engineered U1 snRNAs (eU1) that have extended base 
pairing with the 5′ splice site of exon 7 have been shown to promote exon 7 inclusion in SMN1 
containing exonic mutations that exhibit exon 7 skipping. In this study, eU1 snRNAs that have 
extended base pairing with the 5′ splice site of intron 7 or base pair with sequences downstream 
of the canonical splice donor site are shown to also inhibit exon 7 skipping in a SMN1 allele 
containing a deleterious G-to-C (G1C) mutation at the first position of intron 7. These eU1 
snRNAs prevent exon 7 skipping in the mutant SMN1 allele by promoting intron 7 retention and 
by activating cryptic splice donor sites downstream of the canonical splice donor site. eU1 
snRNAs also promote expression of full length SMN protein in the mutant SMN1 allele. Our 
findings open up yet another avenue for the treatment of SMA patients carrying pathogenic 











Alternative pre-mRNA splicing optimizes the coding potential of a genome by enabling 
single genes to produce multiple transcripts/proteins (Xing and Lee, 2007; Lee and Rio, 2016). 
More than 95% of human genes containing two or more exons undergo alternative splicing 
(Nilsen and Graveley, 2010). For most human genes, GU and AG residues at the beginning and 
the end of an intron serve as the 5ʹ′ splice site (5ʹ′ss) and 3ʹ′ss, respectively (Burge et al., 1999). A 
combinatorial control of cis-elements including exonic or intronic splicing enhancers (ESEs or 
ISEs) and silencers (ESSs or ISSs) define splice sites from among abundantly available GU and 
AG residues within pre-mRNA (Wang and Burge, 2008). Generally, serine and arginine-rich 
proteins (SR proteins) and heteronuclear ribonucleoproteins (hnRNPs) promote and suppress 
exon inclusion by binding to ESEs/ISEs and ESSs/ISSs, respectively. However, there are 
exceptions to the rule as SR proteins and hnRNPs can have negative and positive roles, 
respectively. RNA structures provide another layer of splicing regulation by sequestering or 
exposing regulatory motifs (Buratti and Baralle, 2004; Warf and Berglund, 2010; McManus and 
Graveley, 2011). A RNA sequence can possess multiple interchangeable structures and a 
particular structural confirmation can be stabilized/favored by a specific protein(s). However, 
very little is known how information stored in RNA structures is utilized to regulate pre-mRNA 
splicing.  
 
GURAGU residues at the first six positions and the YAG residues at the last three 
positions of an intron define a typical 5ʹ′ss and 3ʹ′ss in human pre-mRNA, respectively. In 
addition, the definition of the 3ʹ′ss requires presence of a polypyrimidine tract (PPT) and a branch 




pre-mRNAs harbor cryptic splice sites with potential to be activated upon mutations within these 
cryptic sites and/or at the nearby authentic splice sites. It has been shown that the non-authentic 
5ʹ′ss within an exon are suppressed by overlapping ESSs (Wang et al., 2004). Suppression of 
non-authentic intronic splice sites appears to involve a complex network of interactions with 
overlapping ISSs (Wang et al., 2013). Genetic diseases caused by point mutations triggering 
splicing changes without affecting the coding sequence underscore the critical role of splicing 
regulatory elements (Wang et al., 2012; Xiong et al., 2015).  
 
Splicing is catalyzed by the spliceosome, a macromolecular machine in which five small 
ribonucleoproteins (U1, U2, U4, U5 and U6 snRNPs) play an indispensable role (Matlin and 
Moore, 2007; Wahl et al., 2009). The two transesterification steps of pre-mRNA splicing are 
evolutionarily conserved and mimic the splicing of group II introns that are progenitors of the 
spliceosomal introns present in lower organisms (Gaur et al., 1997). Spliceosomal assembly 
begins with the recruitment of U1 snRNP at the 5ʹ′ss of an exon. The RNA component (U1 
snRNA) of U1 snRNP is 165 nucleotides long and folds into four stem-loop structures. The 
protein components of U1 snRNP include a 7-membered ring of Sm proteins (Smith antigens), 
U1-A, U1-70K and U1-C proteins. Both, U1 snRNA and U1-C protein contribute towards the 
recognition of the 5ʹ′ss of an exon (Du and Rosbash, 2002). A driving force behind the 
recruitment of U1 snRNP at the 5ʹ′ss of an exon is the base pairing between the 5ʹ′ tail of U1 
snRNA and the first six positions (GURAGU) of the intron.  
 
The abundance of U1 snRNP happens to be significantly higher than other snRNPs in 




are used as the authentic 5ʹ′ss during pre-mRNA splicing. Recruitment of U1 snRNP at multiple 
sites on pre-mRNA offers several benefits including but not limited to suppression of cryptic 
exons, maintenance of mRNA length and providing directionality to transcription (Pagani et al., 
2002; Almada et al., 2013; Kaida et al., 2010; Berg et al., 2012). An increasing number of reports 
support coupling of splicing with transcription and chromatin structure (Shukla and 
Oberdoerffer, 2012; Naftelberg, 2015; Yu and Reed, 2015; Saldi et al., 2016). However, the 
mechanism of coupling is not yet fully understood.  
 
Humans possess two almost identical copies of survival motor neuron gene, SMN1 and 
SMN2 (Lefebvre, 1995). While SMN1 predominantly produces full-length SMN protein (referred 
to afterwards as “SMN”), SMN2 mostly produces SMNΔ7, a truncated protein, due to 
overwhelming skipping of exon 7 (Lorson et al., 1999; Vitte et al., 2007). In the testis however, 
both SMN genes predominantly produce SMN, possibly due to high demand for SMN during 
male reproductive organ development (Ottesen et al., 2016). Compared to SMN, SMNΔ7 is less 
stable due to gaining of a degron signal at the C-terminus (Cho and Dreyfuss, 2010). 
Consequently, low levels of SMN due to deletions of and/or mutation in SMN1 lead to spinal 
muscular atrophy (SMA), one of the leading genetic causes of infant mortality (Monani et al., 
2014; Ahmad et al., 2016). The spectrum of SMA is broad and ranges from in utero death (type 
0), infants who are symptomatic before the age of six months and die within two years of age 
(type I), individuals who are symptomatic before eighteen months and cannot walk 
independently but can potentially survive into adulthood (type II), individuals who can walk 
independently and have a near average to average lifespan (type III), and individuals with adult-




SMN2 copies that can produce cumulative high levels of SMN and SMNΔ7 ameliorate the 
symptoms of SMA (Parsons et al., 1998; Wirth et al., 2006; Tiziano et al., 2007). Severity of 
SMA is modified by several factors including but not limited to NAIP, GTF2H2, H4F5, p44 and 
Plastin (Tran et al., 2008; Oprea et al., 2008; Amara et al., 2012; He et al., 2013). A recent 
genome-wide analysis of 12 male SMA patients showed association of epigenetic changes in 
regulators of Rab and Rho GTPases with SMA severity (Zheleznyakova et al., 2013).  
 
Skipping of SMN2 exon 7 has been attributed to a critical C-to-T mutation at the 6th 
position of exon 7 (Lorson et al., 1999). Various cis-elements and transacting factors that 
regulate SMN2 exon 7 splicing have been reported (Singh and Singh, 2011; Singh et al., 2015). 
In vivo selection of the entire exon 7 revealed the weak 5ʹ′ss as one of the limiting factors for its 
inclusion (Singh et al., 2004b, 2004c). Consistent with the results of in vivo selection, abrogation 
of the terminal stem-loop 2 (TSL2) structure that sequesters the 5ʹ′ss was found to promote SMN2 
exon 7 inclusion (Singh et al., 2007). Further supporting the results of in vivo selection, an 
engineered U1 snRNP (eU1 snRNP) with extended the base pairing between the 5ʹ′ss of exon 7 
and the 5ʹ′ tail of U1 snRNA promoted SMN2 exon 7 inclusion (Singh et al., 2007). These results 
also provided the first direct evidence that the efficient recruitment of U1 snRNP at the 5ʹ′ss of 
SMN2 exon 7 is necessary and sufficient to restore SMN2 exon 7 inclusion. One of the major 
impediments to an efficient recruitment of U1 snRNP at the 5ʹ′ss of SMN2 exon 7 appears to be 
the presence of the inhibitory element ISS-N1 that spans from the 9th to 24th positions of intron 7 
(Singh et al., 2006). Consistently, deletion or an antisense oligonucleotide (ASO)-mediated 
sequestration of ISS-N1 fully restores SMN2 exon 7 inclusion (Singh et al., 2006). Independent 




vivo (Sivanesan et al., 2013). Sequences downstream of ISS-N1 constitute the binding site for 
TIA1, a splicing factor that promotes recruitment of U1 snRNP at the 5ʹ′ss of an exon (Singh et 
al., 2011). Interestingly, recruitment of a eU1 snRNP in the vicinity of ISS-N1 and/or TIA1 
binding site has been found to restore SMN2 exon 7 inclusion (Dal Mas et al., 2015; Rogalska et 
al., 2016). In addition to ASOs and eU1 snRNP particles, several small compounds that correct 
SMN2 exon 7 splicing have potential for SMA therapy (Seo et al., 2013; Howell et al., 2014).  
 
Research in the last decade has made tremendous progress in determining SMN exon 7 
splicing regulation and novel approaches to correct SMN2 exon 7 splicing. However, SMA still 
has no cure and strategies to treat severe cases remain very daunting. Feasibility of a therapeutic 
approach becomes further limited if the patient carries a single SMN2 allele in combination with 
the deletion and/or lethal mutations of SMN1 alleles. One such classic example of a severe SMA 
patient that survived for only four months has recently been reported (Ronchi et al., 2015). This 
patient carried a single SMN2 allele along with a single SMN1 allele harboring a lethal G-to-C 
mutation at the first position (G1C) of intron 7 (Ronchi et al., 2015). For the ease of 
understanding we designate SMN1G1C as the SMN1 mutant carrying the G1C mutation. Here we 
examine the regulation of SMN1G1C exon 7 splicing employing a translation competent minigene 
system. Recapitulating the severe impact on SMA patient carrying the SMN1G1C gene, the 
SMN1G1C minigene showed complete skipping of exon 7. As a therapeutic strategy, we screened 
a library of eU1 snRNPs to identify a lead eU1 snRNP capable of preventing SMN1G1C exon 7 
skipping as well as activating a potential 5ʹ′ss downstream of the abrogated 5ʹ′ss in SMN1G1C. Our 
approach uncovered two 5ʹ′ss, one at the 23rd position and the other at the 51st position within 




among all eU1 snRNPs employed within the first 60 nucleotides of intron 7. Activation of the 
5ʹ′ss at the 23rd position of intron 7 extended the length of exon 7 by 23 nucleotides. However, 
since translation stop codon of SMN is located within exon 7, activation of the 5ʹ′ss at the 23rd 
position of intron 7 had no consequence to the SMN coding sequence. We demonstrate that the 
eU1 snRNP-based approach to activate the 5ʹ′ss at the 23rd position of intron 7 has therapeutic 






Transcripts derived from SMN1G1C minigene undergo complete exon 7 skipping 
To recapitulate the splicing of SMN1 carrying pathogenic G1C mutation (Ronchi et al., 2015), 
we generated a SMN1G1C minigene in which a single G-to-C mutation was introduced at the first 
position of intron 7 (Figure 4A). As a template, we used SMN1 minigene as previously described 
(Singh et al., 2004a). We determined the splicing pattern of exon 7 of SMN1G1C minigene by 
transfecting SMN1G1C minigene (plasmid) into HeLa cells similarly as recently described (Singh 
et al., 2013). In parallel, we also performed control experiments with SMN1 and SMN2 
minigenes. Transcripts were isolated ~24 h post transfection followed by DNase treatment and 
RT-PCR. Samples were analyzed on a 6% native polyacrylamide gel (OmniPur, 1690-OP). As 
expected, transcripts generated from SMN1 minigene showed predominant inclusion of exon 7 
(Figure 4B, lane 4). Also as expected, transcripts generated from SMN2 minigene showed both 
inclusion and skipping of exon 7 (Figure 4B, lane 3). Recapitulating the splicing of exon 7 from 
endogenous SMN1G1C gene of an SMA patient (Ronchi et al., 2015), SMN1G1C minigene showed 
complete skipping of exon 7 (Figure 4B, lane 5). In the cases of the SMN2 and SMN1G1C 
minigenes, we also detected a faint band corresponding to the unspliced precursor RNA (Figure 
4B, 1063 bp band).  
 
Effect of engineered U1 snRNA on splicing of exon 7 of SMN1G1C minigene  
The presence of a G residue at the first intronic position is critical for both the base pairing with 
the U1 snRNA and the catalytic process during splicing (Lund & Kjems, 2002). In the case of 
SMN1 and SMN2, the wild-type U1 snRNA (wU1) base pairs with six continuous intronic 




wU1 snRNA and the 5ʹ′ss of exon 7 to only five continuous intronic residues (Figure 5A). To 
assess the effect of a strengthened base-pairing between U1 snRNA at the 5ʹ′ss of exon 7 on 
splicing SMN1G1C exon 7, we generated an eU1 snRNA (eU111) carrying five substitutions that 
increased the U1 snRNA base pairing to eleven continuous residues (three exonic and eight 
intronic residues). We co-transfected HeLa cells with SMN1G1C minigene and eU111 and 
examined the splicing pattern of exon 7 of SMN1G1C transcripts. Unlike wU1, eU111 effectively 
prevented SMN1G1C exon 7 skipping and promoted intron 7 retention at all concentrations 
examined (Figure 5B, lanes 6-8). These results suggested that a strong RNA:RNA duplex formed 
by eU111 at the 5ʹ′ss of exon 7 favors intron 6 removal but is not conducive for the removal of 
intron 7. Since the translation stop codon of SMN is located within exon 7, retention of intron 7 
will have no consequence to protein sequence. However, intron 7 retention will increase the size 
of the 3ʹ′ untranslated region (3ʹ′UTR) by 444 nucleotides. The presence of intron 7 and an 
increase in the size of mRNA may adversely affect the nuclear export and/or translation of the 
transcript.   
 
Effect of the 5ʹ′ss:U1 snRNA duplex size on SMN1G1C exon 7 splicing 
Inspired by the results of eU111 that prevented SMN1G1C exon 7 skipping, we next inquired if the 
reduction in the size of the 5ʹ′ss:eU1 duplex will reduce intron 7 retention and favor exon 7 
inclusion from SMN1G1C. We generated eU110A, eU110B, eU11+8C and eU12+6 that reduced the 
5ʹ′ss:eU1 duplex size to 10, 9, 8 and 6 continuous Watson-Crick base pairs, respectively. While 
eU11+8C and eU12+6 formed their duplexes by solely annealing to the intronic sequence, eU110A 
and eU110B had extended base pairing at 2 positions within the exonic sequence (Figure 6A). 




SMN1G1C intron 7. We observed that eU110A was as effective as eU111 in preventing exon 7 
skipping and retaining intron 7 of SMN1G1C (Figure 6B). However, with further decrease in 
5ʹ′ss:eU1 duplex size, we observed more skipping of exon 7 and less retention of SMN1G1C intron 
7 (Figure 6B). There was no effect of eU11+8C and eU12+6 on splicing of SMN1G1C exon 7 (Figure 
6B). We made additional eU1 snRNAs by shifting base pairing positions to see if other variants 
of short (seven or eight base pairs) 5ʹ′ss:eU1 duplexes could stimulate inclusion of SMN1G1C exon 
7. eU11+8A, which formed an 8 bp duplex involving two last residues of exon 7, prevented 
skipping of exon 7 and induced retention of SMN1G1C intron 7 (Figure 6C). Our combined results 
also indicate that the positioning of the 5′ss:eU1 duplex is critical for preventing exon 7 skipping 
(Figures 6B and 6C). None of the eU1 snRNAs promoted intron 7 removal from SMN1G1C. 
Additionally, some eU1s activated a cryptic splice site (Figures 6B, 6C, 6D, 425 bp product). We 
also tested higher concentrations of eU110A to see if removal of SMN1G1C intron 7 could be 
induced. While higher concentrations prevented SMN1G1C exon 7 skipping, they failed to induce 
removal of intron 7 (Figure 6D). These results suggested that SMN1G1C is inherently incompetent 
to initiate the first step of the transesterification process at the 5ʹ′ss of exon 7. 
 
Activation of an alternative 5ʹ′ss downstream of SMN1G1C exon 7  
Another likely mechanism that could induce inclusion of SMN1G1C exon 7 is the activation of an 
alternative 5ʹ′ss downstream of exon 7. Such activation would increase the size of exon 7 without 
affecting the protein sequence. As potential 5ʹ′ splice sites, there are five GU dinucleotides within 
the first 60 residues of SMN1G1C intron 7. The 1st, 2nd, 3rd and 4th GU dinucleotides occupy the 
5th/6th (V1 site), 24th/25th (V2 site), 39th/40th (V3 site), 52nd/53rd (V4 site) intronic positions, 




V2, V3 and V4 sites within intron 7. In particular, we wanted to determine whether the V-series 
eU1 snRNAs could promote the inclusion of elongated forms of exon 7 in SMN1G1C more 
effectively than eU11+8A. For the sake of clarity we term eU1V1, eU1V2, eU1V3 and eU1V4 to eU1 
snRNAs that target V1, V2, V3 and V4 sites, respectively. All V-series eU1 snRNAs formed an 
11 bp long 5ʹ′ss:eU1 duplex (Figure 7A). A clue that alternative 5ʹ′ss downstream of exon 7 could 
be activated came from eU1V4 snRNA that produced two bands from SMN1G1C that ran slower 
than the band from SMN1 that corresponded to transcripts that include exon 7 (Figure 7B, lanes 1 
and 9). Cloning and sequencing of the bands that eU1V4 produced from SMN1G1C revealed the 
inclusion of extended forms of exon 7 due to activation of V2 and/or V4 sites. Activation of V2 
and V4 sites added 23 and 51 residues at the 3ʹ′ end of exon 7, respectively. We call these 
versions of exon 7 with 23 and 51 nucleotide extensions exon 7L1 and exon 7L2, respectively. 
Interestingly, both eU1V2 and eU1V3 produced exon 7L1-included variant as the major spliced 
product. Apart from eU1V2, the other V-series eU1 snRNAs and eU11+8A produced both exon 7L1 
and exon 7L2-included transcripts. In all cases, the proportion of exon 7L1 -included transcripts 
was substantially higher than exon 7L2-included transcripts (Figure 7B; lanes 5-9). 
 
Effect of eU1 snRNAs on splicing of exon 7 from endogenous SMN1 and SMN2  
While eU1 snRNAs altered exon 7 splicing in context of SMN minigenes, we wanted to know if 
eU1 snRNAs also affected endogenous SMN1 and SMN2. We transfected HeLa cells with wU1, 
mutant U1, eU1V2 or eU1V3 expression vectors (Figure 8A). Compared to wU1, mutant U1 has 
extended base pairing with the wild-type 5′ ss of SMN1 and SMN2 intron 7 (Singh et al., 2007; 
Figure 8A). As compared to cells transfected with wU1, mutant U1, eU1V2 and eU1V3 promoted 




that an extended base pairing at either the wild-type splice donor site or at the downstream V2 or 
V3 splice donor sites can alter endogenous SMN2 splicing.  
 
The processed SMN1G1C transcripts encompassing exon 7L1 generate full-length SMN 
After determining that the novel exon 7L1 is included in transcripts generated from SMN1G1C 
minigene when co-transfected with various eU1 snRNA constructs (Figure 7B), we next 
examined whether transcripts containing exon 7L1 could generate a stable protein. We transfected 
HeLa cells with the translation competent minigenes SMN1 and SMN1G1C (Figure 9A). As a 
control we used cDNA clones cSMN and cSMNΔE7. All minigenes or cDNA clones carried 
FLAG tag at the N-terminus. As expected, SMN1 minigene generated SMN that migrated similar 
to SMN generated from cDNA clone of SMN1 (Figure 9A, lanes 1 and 2). The SMN1G1C 
minigene generated multiple bands, two of which corresponded to SMN and SMNΔ7 proteins 
(Figure 9A, lane 3). We also performed a titration experiment to determine how much FLAG-
SMN1 would be required to observe SMN expression (Figure 9B). We observed that transfecting 
0.6 µg of FLAG-SMN1 was sufficient to obtain notable SMN expression (Figure 9B) and we 
used this concentration for subsequent experiments. 
 
 Since the FLAG-SMN1G1C minigene generated protein, we next examined whether 
altering splicing with the eU1V3 would also alter the translated protein. For comparison on 
western blot, we generated the FLAG-SMNI6Δ7 minigene to simulate intron 6 retention. The 
FLAG-SMNI6Δ7 minigene was predicted to generate protein and contains the first 62 bp of 
intron 6, which includes a natural stop codon, but lacks exon 7, intron 7, and the 3′ss of exon 8 




protein. The cSMN- and SMN1-transfected cells generated a full-length SMN protein (Figure 
10C, lanes 1 and 4, respectively). The SMNI6Δ7-transfected cells generated a SMN protein that 
had a similar molecular weight as full-length SMN protein (Figure 10C, lane 3). FLAG-SMNΔ7-
transfected cells generated SMNΔ7 protein (Figure 9C, lane 2). Similarly, FLAG-SMN1G1C-
transfected cells also generated SMNΔ7 protein. However, when cells were co-transfected with 
FLAG-SMN1G1C and eU1V3, the cells produced full-length SMN (Figure 9C, lanes 6-8). Thus, 
activation of the V2 site results into generation of full-length SMN. These results indicate that 
V2 splice site could serve as a therapeutic target to correct defective splicing in SMA patients 






SMA is one of the frequent hereditary causes of infant mortality. A vast majority of SMA 
patients carry SMN2 that produces low levels of SMN. Except for gene therapy, most therapeutic 
approaches under development rely on employment of the existing SMN2 to enhance levels of 
SMN via one of the three potential mechanisms: (i) increased SMN2 transcription, (ii) correction 
of SMN2 exon 7 splicing, and (iii) stabilization of the SMN protein. The expected beneficial 
effects of the SMN2-dependent approaches have a ceiling threshold that cannot be easily crossed 
by low copy numbers of SMN2. In this study, we have addressed this issue for a subset of SMA 
patients with one SMN2 allele and a defective SMN1 carrying a lethal G1C mutation at the splice 
donor site. The approach is inspired by our previous study in which we showed that an extended 
5ʹ′ss:eU1 RNA duplex is favorable for SMN2 exon 7 inclusion (Singh et al., 2007). We reasoned 
that this approach could also be applicable for the prevention of exon 7 skipping in SMN1G1C. 
Indeed, eU1 snRNAs with extended base pairing at the 5ʹ′ss carrying the G1C mutation fully 
prevented exon 7 skipping. However, the major splice product retained intron 7, suggesting that 
G1C is incompetent to carryout splicing reaction. Such an outcome is not totally surprising, since 
a G residue at the first position of an intron is involved in catalysis (Lund & Kjems, 2002).  
 
Intron 7 retention has no consequence to protein sequence in the case of SMN genes. 
Therefore, an ASO-based approach to promote retention of SMN2 intron 7 through blocking of 
the 3ʹ′ss of exon 8 has been considered as one of the possible therapeutic avenues (Lim and 
Hertel, 2001). However, concerns remain that a transcript retaining an intron may not be 
efficiently exported out of the nucleus and efficiently translated. To overcome these issues in the 




mutated 5ʹ′ss in SMN1G1C minigene. Among four potential candidates examined, the 5ʹ′ss (V2 
site) partially overlapping the ISS-N1 emerged as the optimal candidate. The activation of V2 
was robust in the case of eU1 snRNAs that annealed to V2 or V4 sites. In addition to eU1 
snRNA targeting V2 site, other eU1 snRNAs also activated V4 site. However, the extent of V4 
activation did not reach to the level of V2 activation by any of the eU1 snRNAs examined.  
 
Previous studies have shown that eU1 snRNAs targeting ISS-N1 site strengthen the wild-
type 5ʹ′ss of exon 7 and promote SMN2 exon 7 inclusion (Dal Mas, Fortugno et al., 2015). 
Consistent with these findings, eU1 snRNAs used in our study also promoted inclusion of exon 7 
from endogenous SMN2. However, the rules of splicing appear to change in the absence of an 
active 5ʹ′ss of SMN exon 7. In the scenario of the loss of the wild-type 5ʹ′ss of SMN exon 7, V2 
site becomes the next most favorable 5ʹ′ss. Consistent with a transcriptome-wide study supporting 
that silencer elements suppress cryptic 5ʹ′ss (Wang et al., 2004), we hypothesize that ISS-N1 may 
serve such a role by sequestering the V2 site. Several factors may contribute to why V2 site was 
the most activated 5ʹ′ss by a eU1 snRNA in the case of SMN1 carrying the G1C mutation. The 
sequence composition of V2 is very close to the consensus GTRAGT motif of the 5ʹ′ss. The 
binding sites of TIA1 and/or TIAR are located just downstream of V2. TIA1 and TIAR are 
known to promote SMN2 exon 7 inclusion possibly through enhanced recruitment of U1 snRNP 
downstream of the ISS-N1 site (Singh et al., 2011). We have recently reported the secondary 
structure of SMN intron 7. Interestingly, V2 site is located in the most accessible region in the 
structure of intron 7. While all of the above-mentioned factors may have contributed to the 




the driving force behind V2 activation. Consistently, we could not detect appreciable level of V2 
activation in SMN1G1C minigene in the absence of a eU1 snRNA.  
 
Inclusion of exon 7L1 has no consequence to SMN protein. Consistently, a eU1 snRNA 
that targeted V2 site produced SMN from a translation competent SMN1G1C minigene. These 
results confirm that an exon 7L1-containing transcript is nuclear export- and translation-
competent. Our findings open up new therapeutic possibilities for a group of SMA patients who 
would not benefit from most therapeutic approaches currently under development. Since an U1 
snRNA targeting V2 site also promotes exon 7 inclusion from wild-type SMN genes, the 
approach is relevant to a substantial majority of SMA patients. While we have discovered a 
novel therapeutic molecule for treating SMA, determining a method to deliver this molecule in 
vivo is still a challenge. One of the most plausible ways of delivering eU1 snRNAs is through 
most frequently used AAV9-derived viral vectors used in gene therapy. Recent years have 
witnessed tremendous improvements towards gene therapy of SMA (Benkhelifa-Ziyyat et al., 
2013; Meyer et al., 2015). Compared to gene therapy that generates SMN from an artificial gene, 
a eU1 snRNA generates SMN using an endogenous gene. Hence, a eU1 snRNA-based approach 
described here provides a better alternative, since it restores the ability of the defective 









MATERIALS AND METHODS 
Construction of Minigene Containing Pathogenic Mutation 
The SMN1G1C minigene was constructed by inducing a G-to-C substitution at the first 
position of intron 7 in pSMN1∆I6 (Singh et al., 2007). First, two fragments were amplified using 
primer pair 5SMN1Ex6 and 3SMN1E7I7 and primer pair 5SMN1E7I7 and 3SMN1Ex8 using 
pSMN1∆I6 as a template. The two fragments were run on 1% agarose gel, isolated using 
QIAquick Gel Extraction Kit (Qiagen, 28704 and 28706), and then PCR-ligated using primers 
5SMN1Ex6 and 3SMN1Ex8. After gel purification, the PCR product was digested with XhoI 
and NotI for 1 hour, run on 1% agarose gel, and isolated using QIAquick Gel Extraction Kit. The 
purified PCR product was cloned into pCI vector that had been digested with XhoI and NotI for 
1 hour and gel purified. The identity of the SMN1G1C minigene was verified using Sanger DNA 
sequencing (DNA Facility of the Iowa State University Office of Biotechnology, IA). 
 
 The FLAG-SMN1 and FLAG-SMN1G1C minigenes were constructed by adding three 
copies of FLAG tag (3XFLAG) sequence (5′-ATGGACTACAAAGACCATGACGGTGATTAT 
AAAGATCATGACATCGACTACAAAGACGACGATGACAAGACGCGTTCTAGA-3′) and 
SMN1 exons 1 through 5 to the 5′ ends of pSMN1∆I6 and SMN1G1C respectively. First, NdeI cut 
fragments of 3XFLAG-SMN (a pCI-neo-based expression vector that has 3XFLAG sequence 
followed by SMN1 exons 1 through 7) containing exons 2a through 6 were PCR ligated with 
pSMN1∆I6 and SMN1G1C using primer pair 5Ex4 and 3SMN1Ex8. The PCR ligation products 
were then PCR ligated with ApoI cut fragments of 3XFLAG-SMN containing 3XFLAG 
sequence and exons 1 through 5. The PCR products were digested with XhoI and NotI for 1 
hour, run on 1% agarose gel, and isolated using QIAquick Gel Extraction Kit. The purified PCR 




purified. The identities of the FLAG-SMN1 and FLAG-SMN1G1C minigenes were confirmed 
using Sanger DNA sequencing. 
 
The FLAG-SMNI6∆7 minigene was constructed by deleting the last 155 bp of intron 6, exon 
7, intron 7, and the first 24 bp of exon 8 in FLAG-SMN1. Two fragments were amplified using 
primer pair 5Ex8a and PCI-DN and primer pair PCI-UP and 3In7a using FLAG-SMN1 as a 
template. The two fragments were PCR-ligated using PCI-UP and PCI-DN. The PCR product 
was cleaved with XhoI and NotI for 1 hour, run on 1% agarose gel, and isolated using QIAquick 
Gel Extraction Kit. The purified PCR product was cloned into pCI vector that had been digested 
with XhoI and NotI overnight and gel purified. The identity of the FLAG-SMNI6∆7 minigene 
was confirmed using Sanger DNA sequencing. Gels were made using Omnipur agarose 
(OmniPur, 2120-OP).  
 
Construction of U1 snRNA Expression Vectors 
The mutated U1 snRNA expression vectors were constructed using PCR to introduce mutations 
at the 5′ end of U1 RNA. The site-specific mutations were generated using primer 3′pUCBU1 
with primer 5′pUCBU-mutG1C for eU111, 5′pUCBU-mut4 for eU110A, 5′pUCBU-mut3 for 
eU110B, M3V2 for eU11+8A, M3V3 for eU11+8B, M3V4 for eU12+7, 5′pUCBU-mut2 for eU11+8C, 
M2V2 for eU11+8D, 5′pUCBU-mut1 for eU12+6, MI7V1 for eU1V1, MI7V2 for eU1V2, MI7V3 for 
eU1V3, MI7V4 for eU1V4, and plasmid pUCBU1 (Singh et al., 2007) as a template. The PCR 
products were digested with Bg1II and XhoI for 1hour, run on 1% agarose gel, and isolated using 
QIAquick Gel Extraction Kit. The purified PCR products were cloned into pUCB∆U1 vector 




identities of the eU1 snRNAs were verified using Sanger DNA sequencing. Integrated DNA 
Technologies (Coralville, IA) and the DNA Facility of the Iowa State University Office of 
Biotechnology (Ames, IA) supplied the oligonucleotides. 
 
Cell Culture, Transfection, and in vivo splicing 
HeLa cells were obtained from the American Type Culture Collection and were maintained in 
Dulbecco’s Modified Eagle’s Medium (Thermo Fisher Scientific,11965) containing 10% fetal 
bovine serum (Thermo Fisher Scientific, 26140079). Transfections were conducted using X-
tremeGENE (Roche Applied Science, 04476093001 and 04476115001) following the 
manufacturer’s instructions. HeLa cells were plated in either a 24-well or 6-well plate at a 
density of 0.9x105 cells per well or 0.4x106 cells per well, respectively, a day before transfection. 
The ratio between nucleic acids and X-tremeGENE HP DNA Transfection Reagent was 1:2. 
Unless stated otherwise, in co-transfection experiments using either 24-well or 6-well plates, 
cells were transfected with 0.05 µg of a minigene and 0.05 µg of a U1 snRNA expression vector 
or 0.1 µg of minigene and 0.2 µg of U1 snRNA expression vector respectively. Whenever 
necessary, GFP expression vector was added in required amounts to maintain the total amount of 
DNA (0.5 µg in 24-well plates and 2 µg in 6-well plates). 
 
 Total RNA was isolated 20-24 hours after transfection using Trizol reagent (Invitrogen, 
15596018 and 15596026) followed by treatment with RQ1 DNase (Promega, M6101) for 30 
minutes at 37 ˚C. 2 µl of RQ1 DNase Stop was then added to each reaction and incubation 
continued for 10 minutes at 65 ˚C. cDNA was generated using SuperscriptIII reaction kit 




otherwise, 2 µl of DNase reaction were used per 10 µl reverse transcriptase (RT) reaction. After 
mixing 2 µl of DNase eaction with 0.5 µl of oligo (dT)12-18, 0.5 µl 10 mM dNTP, and 4 µl of 
water, RT reaction solutions were heated to 65 ˚C for 5 minutes and incubated on ice for 5 
minutes to denature the RNA. After adding 2 µl of 5X First Strand Buffer, 0.5 µl of 0.1M DTT, 
and 0.5 µl of SuperScript RT, RT reactions were incubated at 50 ˚C for 60 minutes and then 
heated at 70 ˚C for 15 minutes to inhibit the reverse transcriptase.  
 
Minigene-specific spliced products were amplified using Taq polymerase (New England 
Biolabs, M0273S; Invitrogen, 10342-053) and primer pair Ex8P2-2 and PCI-UP or 5CTRL. PCR 
amplification was performed for 30 cycles and used an annealing temperature of 55 ˚C. 
Endogenous SMN1 and SMN2 spliced products were amplified using primers P25 and P31 for 28 
cycles and used an annealing temperature of 54 ˚C. In order to distinguish between amplified 
spliced products from endogenous SMN1 and SMN2, 20 µl of PCR product was used per 100 µl 
DdeI restriction digest reaction that was allowed to incubate overnight (Singh et al., 2011). The 
Qiaquick PCR purification kit (Qiagen, 28704 and 28706) was used to purify DdeI-digested PCR 
products. The PCR products were eluted into 30 µl of EB buffer (10 mM Tris-Cl, pH 8.5). PCR 
products were run at 200 volts on 6% acrylamide gels, which were prepared using 40% 
acrylamide/bisacrylamide stock solution (Omnipur, 1690-OP). PCR products were then stained 
with ethidium bromide (Thermo Fisher Scientific, 15585-011). Spliced products were revealed 
using UVP Biospectrum AC Imaging System (UVP, 81-0346-01). When minigene-specific 
spliced products needed to be quantified, PCR amplification was performed in the presence of 
[α-32P] dATP (Perkin-Elmer Life Sciences, BLU503H250UC) using primers P1 and P2 for 19 




gels at 220 volts. Radioactive acrylamide gels were dried using a Model 583 Gel Dryer (Bio-
Rad, 1651797) and the spliced products were visualized using a Fujifilm FLA-5100 imaging 
system (FUJIFILM Life Science). The PCR products were quantified using ImageGauge 
software (Fuji Photo Film Inc.). The identities of spliced products were verified using Sanger 
DNA Sequencing.  
 
Western blot analysis 
Protein was extracted from HeLa cells 24 hours after transfection. Growth media was removed 
from each well of transfected HeLa cells and the cells were washed once with 2 ml of cold DPBS 
(Thermo Fisher Scientific, 14190250). The DPBS was removed and 1 ml of cold DPBS was 
added to each well of transfected HeLa cells. The HeLa cells were scraped and collected into 
pre-chilled 1.5 ml tubes. The HeLa cell samples were spun at 3500g for 1 minute at 4 ˚C and the 
supernatant of each sample was removed. The cell pellet of each sample was re-suspended in 70 
µl of radioimmunoprecipitation assay (RIPA) buffer (Boston BioProducts, BP-115), containing 
HaltTM Protease and Phosphotase Inhibitor Cocktail (Thermo Fisher Scientific, 78440), and was 
lysed on ice for 30 minutes. The samples were spun at 12000g for 10 minutes at 4 ˚C and the 
supernatant of each sample was collected in pre-chilled 1.5 ml tubes. Protein concentrations were 
calculated using Bradford Protein Assay Kit II (Bio-Rad, 500-0002). 2X Laemmli buffer (Bio-
Rad, 161-0737) containing 5% beta-mercaptoethanol (Calbiochem, 444203) was added to 
protein samples at a 1:1 ratio, and boiled for 5 minutes.  
 
Unless stated otherwise, 10 µg of total protein per sample was resolved on an 11% SDS-




Rad, 1704156) using the Trans-Blot Turbo Transfer System (Bio-Rad, 1704155). PVDF 
membranes were blocked in 5% non-fat milk dissolved in 1X TBST buffer for 30 minutes at 37 
˚C. 1X TBST was composed of 0.05M Tris (pH 7.5), 0.45M NaCl, and 0.05% Tween 20. FLAG-
tagged proteins were probed by incubating blocked PVDF membrane with mouse monoclonal 
anti-FLAG M2 antibody (Sigma-Aldrich, F3165) diluted 1:4000 in 5% non-fat milk dissolved in 
1X TBST for 30 minutes at 37 ˚C. PVDF membranes were then washed three times in 1X TBST 
for 10 minutes each. Proteins were visualized using Bio-Rad Clarity western ECL substrate (Bio-
Rad, 1705060 and 1705061) and PVDF membranes were scanned using a UVP Biospectrum AC 
Imaging System (UVP, 81-0207-01). PVDF membrane images were developed using exposure 
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Figure 4. SMN1G1C minigene exhibits exon 7 skipping. (A) Diagrammatic represenation of the 
SMN1G1C minigene with the intron 7 mutation shown in red. Exon 6, exon 7, and exon 8 are 
indicated as boxes. Intron 6 and intron 7 are indicated as lines. Sizes of exons and introns are 
indicated in base pairs (bp). (B) Splicing pattern of SMN2, SMN1 and SMN1G1C minigenes in 
HeLa cells. Molecular weights are indicated to the left while band identities are shown to the 
right. Above the gel, DNase indicates whether the total RNA was treated with DNase prior to 
reverse transcription and RT indicates whether reverse transcriptase was added to a reaction 
mixture. HeLa cells were plated in 24-well plates at a density of 0.9x105 cells per well. Cells 
were transfected with 0.05 µg of mini-gene and 0.45 µg of GFP expression vector. Total RNA 
was isolated from HeLa cells 24 hours after transfection followed by treating 6 µg of RNA with 
DNase in 20 µl DNase reaction. cDNA was generated using 4 µl of DNase reaction per 10 µl RT 
reaction. PCR products were generated using primers PCI-UP and 3Ex8P2-2 and used 1 µl of RT 
reaction was used per 20 µl Taq PCR reaction. PCR amplification was performed for 30 cycles 
and the annealing temperature (Tm) was 55 ˚C. The PCR products were run on a 6% acrylamide 
gel and were stained with ethidium bromide. 
 
Figure 5. eU1 snRNA with extended base pairing at the 5′ splice site (5′ss) of intron 7 in the 
SMN1G1C minigene promotes intron 7 retention. (A) The sequence of the eU1 snRNA compared 
to wild-type (wU1) U1 snRNA and the 5′ss of intron 7 in SMN1G1C. Mutated nucleotides are 
indicated by red letters. Black circles represent both Watson-Crick and wobble base pairing 
between U1 snRNA and the 5′ss of exon 7. Exon 7 sequence is shown in upper-case letters while 




intron 7. (B) Splicing pattern of SMN1G1C minigene in the presence of wU1 and eU1 snRNA in 
HeLa cells. Band sizes are indicated to the left, band identifies are indicated to the right, and the 
contents for each transfection are indicated above the gel. For lanes 3-8, the amount of each U1 
snRNA expression vector transfected is indicated. HeLa cells were plated in the same manner 
described in Figure 4B. Cells were transfected with 0.05 µg of mini-gene and 0.05 µg, 0.2 µg, or 
0.5 µg of a given U1 snRNA expression vector. GFP expression vector was added when 
necessary to maintain a total amount of 0.5 µg of DNA in each transfection. Total RNA was 
isolated from HeLa cells 22 hours after transfection followed by treating 6 µg of RNA with 
DNAse in 20 µl DNase reaction. cDNA was generated using 7 µl of DNase reaction per 20 µl 
RT reaction. PCR products were generated, run on a 6% acrylamide gel, and stained in the same 
manner described in Figure 4B.  
 
Figure 6. The effect of different eU1 snRNAs with differing degrees of extended base pairing 
with the 5′ ss of exon 7 on SMN1G1C splicing.  (A) The sequences of the eU1 snRNAs compared 
to the wU1 snRNA. Names of U1 snRNAs are shown on the left. Red letters indicate mutations 
compared to wild-type U1 snRNA (wU1). Black circles indicate Watson-Crick and wobble base 
pairs formed between U1 snRNAs and the 5′ss of exon 7. Exon 7 sequence is shown in upper-
case letters while intron 7 sequence is shown in lower-case letters. (B) Splicing pattern of 
minigenes and eU1 snRNA in HeLa cells. Band sizes are indicated to the left and band identities 
are indicated to the right of the gel. The minigenes and eU1 transfected for each sample are 
indicated above the gel. HeLa cells were plated in 6-well plates at a density of 4.8x105 cells per 
well. Cells were transfected with 1 µg of mini-gene and 1 µg of either U1 snRNA expression 




transfection followed by treating 8 µg of RNA with DNAse in 20 µl DNase reaction. cDNA was 
generated in the same manner described in Figure 4B. PCR products were generated in the same 
manner described in Figure 4B, except 1 µl cDNA was used per 25 µl Taq PCR reaction. PCR 
products were run on a 6% acrylamide gel and stained in the same manner described in Figure 
4B. (C) Splicing pattern of minigenes with different eU1 in HeLa cells. HeLa cells were plated 
as described in Figure 6B. Cells were transfected with 0.1 µg of mini-gene and 0.2 µg of a given 
U1 snRNA expression vector. GFP was added when necessary to maintain a total amount of 2 µg 
of DNA in each transfection. Total RNA was isolated from HeLa cells 21 hours after transfection 
followed by treating 1 µg of RNA with DNase in 10 µl DNase reaction. cDNA was generated 
using 2 µl of DNase reaction per 10 µl RT reaction. PCR products were generated in the same 
manner described in Figure 4B. PCR products were run on a 6% acrylamide gel and stained in 
the same manner described in Figure 4B. (D) Splicing of SMN1G1C minigene with different 
concentrations of eU110A in HeLa cells. Molecular size is indicated to the left, band identities are 
indicated to the right, and the minigenes transfected in HeLa cells are indicated at the top of the 
gel. HeLa cells were plated as described in Figure 6B. Cells were transfected with 0.1 µg of 
mini-gene and 0.2 µg, 0.5 µg, or 1 µg of eU110A snRNA expression vector. GFP expression 
vector was added when needed to maintain a total amount of 2 µg of DNA in each transfection. 
Total RNA was isolated from HeLa cells 23 hours after transfection followed by treating 6 µg of 
RNA with DNAse in 20 µl DNase reaction. cDNA was generated in the same manner described 
in Figure 5B. PCR products were generated in the same manner described in Figure 4B, except 1 
µl cDNA was used per 25 µl Taq PCR reaction. The PCR products were run on a 6% acrylamide 





Figure 7. The effects of eU1 snRNAs targeting different splice donor sites in the SMN1G1C 
minigene. (A) eU1 snRNAs and their annealing sites within intron 7 in SMN1G1C. Mutated 
nucleotides in are indicated by red letters. Exon 7 sequence is shown in upper-case letters while 
intron 7 sequence is shown in lower-case letters. Mutated 5′ss is shown in red. Distances 
between splice sites are indicated as nucleotides (nt). GU dinucleotides are marked with blue 
squares. Numbering starts from the first position of intron 7. (B) Splicing patterns of SMN1G1C 
minigene in the presence of different eU1 snRNAs in HeLa cells. Product identities and their 
sizes are indicated on the right side of the gel. Ex6S denotes a shortened form of exon 6 in which 
the GU dinucleotide at the 61st/62nd positions in exon 6 act as a cryptic splice donor site. The 
percentages of exon 7 were calculated from the total value of exon 7-included and exon 7-
skipped products. HeLa cells were plated as described in Figure 4B. Cells were transfected with 
0.05 µg of minigene and 0.05 µg of U1 snRNA expression vector. Empty pCI vector was added 
when needed to maintain a total amount of 0.5 µg of DNA in each transfection. Total RNA was 
isolated from HeLa cells 24 hours after transfection followed by DNase treating RNA. DNAse 
treated RNA was phenol extracted and ethanol precipitate. cDNA was generated using 0.5 µg of 
total RNA per 5 µl RTase reaction. PCR products were generated using primers P2 and P1 and 
used 4 µl of RTase reaction per 50 µl PCR reaction. PCR amplification was performed for 19 
cycles in the presence of [α-32P] dATP and used an annealing temperature of 60 ˚C. The PCR 
products were separated on a 6% acrylamide gel. 
 
Figure 8. eU1 snRNA can alter splicing of endogenous SMN2. (A) U1 snRNA mutants and their 
annealing sites at the 5′ss of exon 7 and within intron 7. Red nucleotides show mutations that 




activate the V2 alternative splice site. Exon 7 sequence is shown in upper-case letters while 
intron 7 sequence is shown in lower-case letters. (B) Splicing pattern of endogenous SMN1 and 
SMN2 in HeLa cells in the presence of different U1 snRNAs as indicated in Figure 8A. To 
distinguish between SMN1 and SMN2, PCR products were digested with DdeI (Singh et al., 
2011). The identity of the band (SMN1- or SMN2-derived) is indicated to the right of the gel and 
the presence or absence of intron 7 or exon 7 is indicated to the left of the gel. HeLa cells were 
plated as described in Figure 4B. Cells were transfected 0.05 µg of a given U1 snRNA 
expression vector and 0.45 µg of pCI vector. Total RNA was isolated from HeLa cells and 
treated with DNase in the same manner described in Figure 6C. PCR products were generated 
using primers P25 and P31 and used 1 µl of RT reaction per 25 µl Taq PCR reaction. PCR 
amplification was performed for 28 cycles and used an annealing temperature of 54˚C. PCR 
products were digested with DdeI overnight and then run on a 6% acrylamide gel and stained in 
the same manner described in Figure 4B. 
 
Figure 9. Protein expression in FLAG-tagged SMN minigenes. (A) Diagrammatic representation 
and protein expression from FLAG-SMN1G1C minigene. HeLa cells were transfected with various 
minigenes and the translated protein was analyzed by Western blot using an anti-FLAG antibody 
conjugated to horseradish peroxidase. FLAG-SMN1 was identical to FLAG-SMN1G1C except the 
first position of intron 7 did not carry the G-to-C mutation (shown in red). FLAG-cSMN 
contained the nine SMN1 exons with no introns. FLAG-cSMNΔ7 contained all exons except exon 
7 and had no introns. The molecular weight ladder is indicated to the left of the blot and the size 
for full-length FLAG-SMN (38.4 kDa) and truncated FLAG-SMNΔ7 (36.96 kDa) are indicated 




transfected with 2 µg of a given FLAG-tagged SMN mini-gene. Total protein was isolated from 
HeLa cells 24 hours after transfection. A total of 10 µg of protein was used for samples 
corresponding to SMN1, cSMN, SMN1G1C, while a total of 20 µg of protein was used for the 
sample corresponding to cSMN∆E7. Lysates were run on 11% SDS-polyacrylamide gel. The 
image was developed using an exposure time of 13 seconds. (B) Titration experiment to 
determine the required amount of FLAG-SMN1 minigene to observe FLAG-tagged SMN 
expression. Minigenes are the same as described in (A). Molecular-weight marker is indicated to 
the left of the gel. HeLa cells were plated in the same manner described in Figure 6B. Cells were 
transfected with 0.2 µg, 0.6 µg, or 2 µg of FLAG-tagged mini-gene. pCI was added when 
necessary to maintain a total of 2 µg of DNA in each transfection. Protein was isolated from 
HeLa cells and prepared as described in Figure 9A. A total of 10 µg of protein was used per 
sample. Proteins were resolved as described in Figure 9A. The image was developed using an 
exposure time of 11 seconds. (C) Diagrammatic representation and splicing pattern of SMNI6∆7 
minigene, which is designed to simulate intron 6 retention in SMN1. HeLa cells were plated in 
the same manner described in Figure 6B and were transfected with 2 µg of SMNI6∆7 minigene. 
Total RNA was isolated 24 hours after transfection from an aliquot of HeLa cells collected in 
200 µl of DPBS Buffer. DNase treatment of RNA and generation of cDNA were done in the 
same manner described in Figure 6C. PCR products were generated using primers 5CTRL and 
PS-SMN-exon8 and used 1 µl of RT reaction per 25 µl Taq PCR reaction. PCR amplification 
conditions were the same as described in Figure 4B. The PCR products were run on a 6% 
acrylamide gel and stained in the same manner described in Figure 4B. (D) FLAG western blot 
to examine protein expression in HeLa cells. The minigenes transfected in HeLa cells are 




length FLAG-SMN (38.4 kDa) and FLAG-SMNΔ7 (36.96 kDa) bands are indicated to the right 
of the gel. HeLa cells were plated in the same manner described in Figure 6B. Cells were 
transfected with 0.6 µg of a FLAG-tagged SMN mini-gene and 0.6 µg, 1 µg, or 1.4 µg of eU1V3 
snRNA expression vector. Protein was isolated from HeLa cells and prepared as described in 
Figure 9A. While a total of 10 µg of protein was used for samples, a total of 15 µg of protein was 
used for the sample corresponding to cSMN∆E7. Proteins were resolved and probed as described 






















































Figure 5. eU1 snRNA with extended base pairing at the 5′ splice site (5′ss) of intron 7 in the 































Figure 6. The effect of eU1 snRNAs with differing degrees of extended base pairing with the 5′ 


























































































































CHAPTER 3. GENERAL CONCLUSIONS 
 
Mutations that cause aberrant splicing are present in a variety of genetic diseases. In 
patients afflicted with Spinal muscular atrophy (SMA), a C-to-T mutation in exon 7 that weakens 
the 5ʹ′ss of the exon triggers exon 7 skipping and prevents SMN2 from being able to compensate 
for the loss of SMN1. In deleterious SMN1 alleles such as SMN1G1C, mutations at the 5ʹ′ss of exon 
7 induce skipping by preventing intron 7 from being spliced out. U1 snRNPs with snRNAs that 
have extended base pairing with the 5ʹ′ss or an alternative splice donor site could be used to 
correct splicing in deleterious SMN1 alleles as well as SMN2. 
 
In chapter 2, we demonstrated that expression vectors for engineered U1 snRNAs (eU1s) 
could be used to inhibit exon 7 skipping in both SMN1G1C and SMN2. eU1s that target the 
mutated 5ʹ′ss of exon 7 in SMN1G1C promote intron 7 retention and weakly activate splice site 
(V2) that can redefine exon 7.  The eU1s designed to bind to potential splice sites downstream of 
the mutated exon 7 splice donor site can promote the usage of splice sites at the 23rd position and 
the 51st position of intron 7 more effectively than the eU1s directly targeting the mutated 5ʹ′ss of 
exon 7. eU1s targeting downstream of the 5ʹ′ss of exon 7 can also prevent exon 7 skipping in 
SMN2. Additionally, eU1s targeting alternative splice sites prevents exon 7 skipping to a great 
enough extent to promote full-length SMN protein in SMN1G1C. Overall, the study indicates the 
identification of “novel” splice donor sites in SMN genes and that the eU1s targeting the 
alternative sites have potential to be a general treatment for SMA patients, and possibly other 









Supplementary Table 1. List of primers used for PCR. E and I are abbreviations for exon and 
intron respectively. Tm indicates the melting point of a primer in degrees Celsius. 
 








3In7a Reverse CTTTAGTGGTGTCATTTACAAAACAAAGTC 55.3 I6 
3′pUCBU1 Reverse  ATCCTCGAGCCTCCACTGTAGGATTAAC 60.9 PUCBU1 
3SMN1E7I7 Reverse CTTTCATAATGCTGGCAGACTTAGTCCTTAATTT
AAGG 
60	   E7 
3SMN1Ex8 Reverse TCGAAGCGGCCGCCCGGGCACATACG 72.1	   E8 
5Ex8a Forward GACTTTGTTTTGTAAATGACACCACTAAAG  55.3	   E8 
5′pUCBU-
mut1   
Forward CGAAGATCTCATACTTAGCTGGCAGGGGAGAT 63.2	   PUCBU1 
5′pUCBU-
mut2   
Forward CGAAGATCTCAGACTTAGCTGGCAGGGGAGAT  64.6	   PUCBU1 
5′pUCBU-
mut3 
Forward CGAAGATCTCAGACTTAGTTGGCAGGGGAGAT  63.3	   PUCBU1 
5′pUCBU-
mut4 
Forward CGAAGATCTCAGACTTAGTCGGCAGGGGAGAT 64.4	   PUCBU1 
5′pUCBU-
mutG1C 
Forward CGAAGATCTCAGACTTAGTCCGCAGGGGAGAT  64.4	   PUCBU1 
5Ex4 Forward CCAAATCTGCTCCATGGAACTCTTTTC  58.1	   E4 
5SMN1E7I7 Forward AAGGTGCTCACATTCCTTAAATTAAGGACTAAG
TCTGC 
 62	   I7 
5SMN1Ex6 Forward CTATGGCTAGCCTCGAGATAATTCC 56.4 	   E6 
Ex8P2-2   Reverse  CTTCCTTTTTTCTTTCCCAACAC  52.8	   E8 
M2V2 Forward CGAAGATCTCATACTTAGTTGGCAGGGGAGAT  61.8	   PUCBU1 
M3V2 Forward CGAAGATCTCATACTTAGTCGGCAGGGGAGAT  62.9	   PUCBU1 
M3V3 Forward CGAAGATCTCAGACTTAGCCGGCAGGGGAGAT  66.1	   PUCBU1 
M3V4 Forward CGAAGATCTCAGACTTACTCGGCAGGGGAGAT  64.4	   PUCBU1 
MI7V1 Forward CGAAGATCTCTGGCAGACTTAGCAGGGGAGAT  64.6	   PUCBU1 
MI7V2 Forward CGAAGATCTCAGATTCACTTTGCAGGGGAGAT  62.4	   PUCBU1 
MI7V3 Forward CGAAGATCTCAGTTTTACAAAGCAGGGGAGAT  61.1	   PUCBU1 
MI7V4 Forward CGAAGATCTCCCACAAACCATGCAGGGGAGAT 65.6 	   PUCBU1 
P1 Forward CGACTCACTATAGGCTAGCC  54	   PCI 
P2 Reverse GCATGCAAGCTTCCTTTTTTCTTTCCCAACAC  62.2	   E8 
P25 Reverse CTCGAAGCGGCCGCAGCTCATAAAATTACCA  65	   E8 
P31 Forward CATCAGTGGCTATCATACTG  50	   PCI 
PCI-DN Reverse AGCATCACAAATTTCACAAATAAA  50.2	   PCI 





MUTATIONS DISRUPTING RNA SPLICING 
Supplementary Table 2. Documented Mutations Disrupting U1 snRNP Activity 
Gene Locationa Mutationb Predicted Changec Reference(s) 
FUS E14 c.1483C>T p.R495X 
(Calvo et al., 2014;Yu et al., 
2015; Sun et al., 2015) 
FUS E15 c.1561C>T p.R521G 
(Calvo et al., 2014;Yu et al., 
2015; Sun et al., 2015) 
FUS E15 c.1574C>T p.P525L 
(Calvo et al., 2014;Yu et al., 
2015; Sun et al., 2015) 
SNRPB I2 c.164G>C 
Mutation in intron 2 promotes 
alternative exon with PTC 
(Lynch et al., 2014; Bacrot et 
al., 2015) 
SNRPB I2 c.164G>T 
Mutation in intron 2 promotes 
alternative exon with PTC 
(Lynch et al., 2014; Bacrot et 
al., 2015) 
SNRPB I2  c.165G>C 
Mutation in intron 2 promotes 
alternative exon with PTC 
(Lynch et al., 2014; Bacrot et 
al., 2015) 
SNRPB I2 c.166G>C 
Mutation in intron 2 promotes 
alternative exon with PTC 
(Lynch et al., 2014; Bacrot et 
al., 2015) 
SNRPB I2 c.213+57C>A 
Mutation in intron 2 promotes 
alternative exon with PTC (Bacrot et al., 2015) 
 
a E refers to exon; I refers to intron. 
b Nucleotide numbering refers to the coding sequence with A of ATG denoted as +1.                    























Supplementary Table 2. Documented Mutations Disrupting Splice Sites 
Gene Locationa Mutationb Predicted Change Reference(s) 
IKBKAP I20 c.2204+6T>C Mutation in intron 20 splice donor site 
(Slaugenhaupt et al., 
2001; Ibrahim et al., 
2007) 
BBS1 E5 c.479G>A Mutation in exon 5 splice donor site (Schmid et al., 2011) 
SPINK5 I2 c.81+2T>A 
Mutation in conserved consensus intron 2 
donor splice site; exon 2 skipped (Bitoun et al., 2002) 
SPINK5 E1 c.56G>A Mutation in exon 1 splice donor site (Bitoun et al., 2002) 
SPINK5 I20 c.1888-1G>A 
Mutation in conserved consensus intron 20 
acceptor splice site; exon 21 skipped (Bitoun et al., 2002) 
SPINK5 I23 c.2240+1G>A 
Mutation in conserved consensus intron 23 
donor splice site; exon 23 skipped (Bitoun et al., 2002) 
SPINK5 I2 c.81+5G>A Mutation in intron 2 splice donor site (Bitoun et al., 2002) 
SPINK5 I17 c.1698-1G>A 
Mutation in conserved consensus intron 17 
acceptor splice site; exon 18 skipped (Bitoun et al., 2002) 
SPINK5 E11 c.891C>T 
Mutation in exon 11 promotes hnRNP 
binding; exon 11 skipped 
(Dal Mas, Fortugno, et 
al., 2015) 
CFTR I5 c.711+1G>T 
Mutation in conserved consensus intron 5 
donor splice site; exon 5 skipped (Fanen et al., 1992) 
CFTR I10 c.1717-1G>A 
Mutation in conserved consensus intron 10 
acceptor splice site; exon 11 skipped (Fanen et al., 1992) 
CFTR I11 c.1811+1600A>G Mutation in intron 11 produces a new exon (Chillón et al., 1995) 
CFTR I14b c.2789+5G>A Mutation in intron 14b splice donor site (Fanen et al., 1992) 
CFTR I17a c.3272-26A>G 
Mutation in intron 17a produces alternative 
acceptor site (Fanen et al., 1992) 
CFTR I23 c.4374+1G>A 
Mutation in conserved consensus intron 23 
donor splice site; exon 23 skipped (Fanen et al., 1992) 
hSNF5 I7 c.986+1G>A 
Mutation in conserved consensus intron 7 
donor splice site; exon 7 skipped 
(Venables, 2004; 
Eaton et al., 2011) 
APC I3 c.423-1G>T 
Mutation in conserved consensus intron 3 
acceptor splice site; exon 4 skipped 
(Venables, 2004; 
Friedl & Aretz, 2005) 
CCND1 E4 c.870G>A Mutation in exon 4 splice donor site 
(David & Manley, 
2010) 
SMN1 I7 c.888+1G>C 
Mutation in conserved consensus intron 7 
donor splice site; exon 7 skipped (Ronchi et al., 2015) 
 
a E refers to exon; I refers to intron 
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SMN MUTATIONS AT EXON 7 AND INTRON 7 IN SMA PATIENTS 
Supplementary Table 3. Documented SMN mutations at exon 7 and intron 7 in SMA patients. 
 
a E refers to exon; I refers to intron 
b Nucleotide numbering refers to the coding sequence with A of ATG denoted as +1.                    
c Amino acids are indicated by their three letter codes; an X denotes a premature stop codon 











Locationa Nucleotide Changeb Predicted Changec SMA Patient Types Reference(s) 
Missense Mutations 
E7 c.835 G>T p.Gly279Cys II, III (Wang et al., 1998) 
E7 c.836 G>T p.Gly279Cys I (Hahnen et al., 
1997) 
E7 c.859 G>Cd p.Gly287Arg II, III (Bernal et al., 2010; 
Verzain et al., 
2010) 
E7 c.863 G>T p.Arg288Met I, II (Qu et al., 2015) 
Nonsense Mutations 
E7 c.861_862insT p.Arg288X II (Ganji et al., 2015) 
Splice Site Mutations  
I7 c.888+1G>C Mutation in 
conserved 
consensus intron 7 
donor splice site; 
exon 7 skipped 
I (Ronchi et al., 
2015) 
I7 c.889+3delAGTC Deletion at intron 7 
splice donor site 
II (Lefebvre et al., 
1995) 
I7 c.889+6T>G Mutation in intron 
7 splice donor site 
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APPENDIX D  
SEQUENCES OF SMN MINIGENES  
Key	  for	  minigenes:	  
FLAG:	  Red	  …	  
Exon	  1:	  Yellow	  …	  
Exon	  2a:	  Bright	  Green	  …	  
Exon	  2b:	  Bright	  Blue	  …	  
Exon	  3:	  Pink	  …	  
Exon	  4:	  Blue	  …	  
Exon	  5:	  Teal	  …	  
Exon	  6:	  Green	  …	  
Delta	  Intron	  6:	  Purple	  …	  
Exon	  7:	  Orange	  …	  
Intron	  7:	  Dark	  Yellow	  …	  
Exon	  8:	  Gray	  …	  
XhoI	  site:	  CTCGAG	  
NotI	  site:	  GCGGCCG	  
NdeI	  site:	  CATATG	  




































































































































































































































































































































SEQUENCES OF U1 snRNA EXPRESSION VECTORS 
 
Key for expression vectors: 
U1 snRNA: Yellow … 
Mutations: Red text 
XhoI site: CTCGAG 
Bg1II site: AGATCT 
 
 
wU1 
 
AGATCTCATACTTACCTGGCAGGGGAGATACCATGATCACGAAGGTGGTTTTCCCA
GGGCGAGGCTTATCCATTGCACTCCGGATGTGCTGACCCCTGCGATTTCCCCAAATG
TGGGAAACTCGACTGCATAATTTGTGGTAGTGGGGGACTGCGTTCGCGCTTTCCCCT
GACTTTCTGGAGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTT
GGTTTGTGTCTTGGTTGGCGTCTTAAATGTTAATCCTACAGTGGAGGCTCGAG 
 
 
Mutant U1 
 
AGATCTCAGACTTACTCCGCAGGGGAGATACCATGATCACGAAGGTGGTTTTCCCA
GGGCGAGGCTTATCCATTGCACTCCGGATGTGCTGACCCCTGCGATTTCCCCAAATG
TGGGAAACTCGACTGCATAATTTGTGGTAGTGGGGGACTGCGTTCGCGCTTTCCCCT
GACTTTCTGGAGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTT
GGTTTGTGTCTTGGTTGGCGTCTTAAATGTTAATCCTACAGTGGAGGCTCGAG 
 
 
eU111 
 
AGATCTCAGACTTAGTCCGCAGGGGAGATACCATGATCACGAAGGTGGTTTTCCCA
GGGCGAGGCTTATCCATTGCACTCCGGATGTGCTGACCCCTGCGATTTCCCCAAATG
TGGGAAACTCGACTGCATAATTTGTGGTAGTGGGGGACTGCGTTCGCGCTTTCCCCT
GACTTTCTGGAGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTT
GGTTTGTGTCTTGGTTGGCGTCTTAAATGTTAATCCTACAGTGGAGGCTCGAG 
 
 
eU110A 
 
AGATCTCAGACTTAGTCGGCAGGGGAGATACCATGATCACGAAGGTGGTTTTCCCA
GGGCGAGGCTTATCCATTGCACTCCGGATGTGCTGACCCCTGCGATTTCCCCAAATG
TGGGAAACTCGACTGCATAATTTGTGGTAGTGGGGGACTGCGTTCGCGCTTTCCCCT
GACTTTCTGGAGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTT
GGTTTGTGTCTTGGTTGGCGTCTTAAATGTTAATCCTACAGTGGAGGCTCGAG 
 
 
	  
	  
74	  
eU110B 
 
AGATCTCAGACTTAGTTGGCAGGGGAGATACCATGATCACGAAGGTGGTTTTCCCA
GGGCGAGGCTTATCCATTGCACTCCGGATGTGCTGACCCCTGCGATTTCCCCAAATG
TGGGAAACTCGACTGCATAATTTGTGGTAGTGGGGGACTGCGTTCGCGCTTTCCCCT
GACTTTCTGGAGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTT
GGTTTGTGTCTTGGTTGGCGTCTTAAATGTTAATCCTACAGTGGAGGCTCGAG 
 
 
eU11+8C 
 
AGATCTCAGACTTAGCTGGCAGGGGAGATACCATGATCACGAAGGTGGTTTTCCCA
GGGCGAGGCTTATCCATTGCACTCCGGATGTGCTGACCCCTGCGATTTCCCCAAATG
TGGGAAACTCGACTGCATAATTTGTGGTAGTGGGGGACTGCGTTCGCGCTTTCCCCT
GACTTTCTGGAGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTT
GGTTTGTGTCTTGGTTGGCGTCTTAAATGTTAATCCTACAGTGGAGGCTCGAG 
 
 
eU12+6 
 
AGATCTCATACTTAGCTGGCAGGGGAGATACCATGATCACGAAGGTGGTTTTCCCA
GGGCGAGGCTTATCCATTGCACTCCGGATGTGCTGACCCCTGCGATTTCCCCAAATG
TGGGAAACTCGACTGCATAATTTGTGGTAGTGGGGGACTGCGTTCGCGCTTTCCCCT
GACTTTCTGGAGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTT
GGTTTGTGTCTTGGTTGGCGTCTTAAATGTTAATCCTACAGTGGAGGCTCGAG 
 
 
eU11+8D 
 
AGATCTCATACTTAGTTGGCAGGGGAGATACCATGATCACGAAGGTGGTTTTCCCA
GGGCGAGGCTTATCCATTGCACTCCGGATGTGCTGACCCCTGCGATTTCCCCAAATG
TGGGAAACTCGACTGCATAATTTGTGGTAGTGGGGGACTGCGTTCGCGCTTTCCCCT
GACTTTCTGGAGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTT
GGTTTGTGTCTTGGTTGGCGTCTTAAATGTTAATCCTACAGTGGAGGCTCGAG 
 
 
eU11+8A 
 
AGATCTCATACTTAGTCGGCAGGGGAGATACCATGATCACGAAGGTGGTTTTCCCA
GGGCGAGGCTTATCCATTGCACTCCGGATGTGCTGACCCCTGCGATTTCCCCAAATG
TGGGAAACTCGACTGCATAATTTGTGGTAGTGGGGGACTGCGTTCGCGCTTTCCCCT
GACTTTCTGGAGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTT
GGTTTGTGTCTTGGTTGGCGTCTTAAATGTTAATCCTACAGTGGAGGCTCGAG 
 
 
 
	  
	  
75	  
eU11+8B 
 
AGATCTCAGACTTAGCCGGCAGGGGAGATACCATGATCACGAAGGTGGTTTTCCCA
GGGCGAGGCTTATCCATTGCACTCCGGATGTGCTGACCCCTGCGATTTCCCCAAATG
TGGGAAACTCGACTGCATAATTTGTGGTAGTGGGGGACTGCGTTCGCGCTTTCCCCT
GACTTTCTGGAGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTT
GGTTTGTGTCTTGGTTGGCGTCTTAAATGTTAATCCTACAGTGGAGGCTCGAG 
 
 
eU12+7 
 
AGATCTCAGACTTACTCGGCAGGGGAGATACCATGATCACGAAGGTGGTTTTCCCA
GGGCGAGGCTTATCCATTGCACTCCGGATGTGCTGACCCCTGCGATTTCCCCAAATG
TGGGAAACTCGACTGCATAATTTGTGGTAGTGGGGGACTGCGTTCGCGCTTTCCCCT
GACTTTCTGGAGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTT
GGTTTGTGTCTTGGTTGGCGTCTTAAATGTTAATCCTACAGTGGAGGCTCGAG 
 
 
eU1V1 
 
AGATCTCTGGCAGACTTAGCAGGGGAGATACCATGATCACGAAGGTGGTTTTCCCA
GGGCGAGGCTTATCCATTGCACTCCGGATGTGCTGACCCCTGCGATTTCCCCAAATG
TGGGAAACTCGACTGCATAATTTGTGGTAGTGGGGGACTGCGTTCGCGCTTTCCCCT
GACTTTCTGGAGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTT
GGTTTGTGTCTTGGTTGGCGTCTTAAATGTTAATCCTACAGTGGAGGCTCGAG 
 
 
eU1V2 
 
AGATCTCAGATTCACTTTGCAGGGGAGATACCATGATCACGAAGGTGGTTTTCCCA
GGGCGAGGCTTATCCATTGCACTCCGGATGTGCTGACCCCTGCGATTTCCCCAAATG
TGGGAAACTCGACTGCATAATTTGTGGTAGTGGGGGACTGCGTTCGCGCTTTCCCCT
GACTTTCTGGAGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTT
GGTTTGTGTCTTGGTTGGCGTCTTAAATGTTAATCCTACAGTGGAGGCTCGAG 
 
 
eU1V3 
 
AGATCTCAGTTTTACAAAGCAGGGGAGATACCATGATCACGAAGGTGGTTTTCCCA
GGGCGAGGCTTATCCATTGCACTCCGGATGTGCTGACCCCTGCGATTTCCCCAAATG
TGGGAAACTCGACTGCATAATTTGTGGTAGTGGGGGACTGCGTTCGCGCTTTCCCCT
GACTTTCTGGAGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTT
GGTTTGTGTCTTGGTTGGCGTCTTAAATGTTAATCCTACAGTGGAGGCTCGAG 
 
 
 
	  
	  
76	  
eU1V4 
 
AGATCTCCCACAAACCATGCAGGGGAGATACCATGATCACGAAGGTGGTTTTCCCA
GGGCGAGGCTTATCCATTGCACTCCGGATGTGCTGACCCCTGCGATTTCCCCAAATG
TGGGAAACTCGACTGCATAATTTGTGGTAGTGGGGGACTGCGTTCGCGCTTTCCCCT
GACTTTCTGGAGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTT
GGTTTGTGTCTTGGTTGGCGTCTTAAATGTTAATCCTACAGTGGAGGCTCGAG 
 
 
 
 
 
	  
 
 
 
 
 
	  
